Literature DB >> 19687473

Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.

Timo T Myöhänen1, J Arturo García-Horsman, Jofre Tenorio-Laranga, Pekka T Männistö.   

Abstract

Prolyl oligopeptidase (POP) is a serine endopeptidase that hydrolyses proline-containing peptides shorter than 30 amino acids. POP may be associated with cognitive functions, possibly via the cleavage of neuropeptides. Recent studies have also suggested novel non-hydrolytic and non-catalytic functions for POP. Moreover, POP has also been proposed as a regulator of inositol 1,4,5-triphosphate signaling and several other functions such as cell proliferation and differentiation, as well as signal transduction in the central nervous system, and it is suspected to be involved in pathological conditions such as Parkinson's and Alzheimer's diseases and cancer. POP inhibitors have been developed to restore the depleted neuropeptide levels encountered in aging or in neurodegenerative disorders. These compounds have shown some antiamnesic effects in animal models. However, the mechanisms of these hypothesized actions are still far from clear. Moreover, the physiological role of POP has remained unknown, and a lack of basic studies, including its distribution, is obvious. The aim of this review is to gather information about POP and to propose some novel roles for this enzyme based on its distribution and its discordant spatial association with its best known substrates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687473      PMCID: PMC2728128          DOI: 10.1369/jhc.2009.953711

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  146 in total

Review 1.  Behavioral neuroendocrinology of vasotocin and vasopressin and the sensorimotor processing hypothesis.

Authors:  James D Rose; Frank L Moore
Journal:  Front Neuroendocrinol       Date:  2002-10       Impact factor: 8.606

2.  Molecular cloning of cDNA for Sarcophaga prolyl endopeptidase and characterization of the recombinant enzyme produced by an E. coli expression system.

Authors:  S Ohtsuki; K Homma; S Kurata; S Natori
Journal:  Insect Biochem Mol Biol       Date:  1997-04       Impact factor: 4.714

3.  Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells.

Authors:  M Shinoda; K Toide; I Ohsawa; S Kohsaka
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

Review 4.  Thyrotropin-releasing hormone receptors -- similarities and differences.

Authors:  Y Sun; X Lu; M C Gershengorn
Journal:  J Mol Endocrinol       Date:  2003-04       Impact factor: 5.098

5.  ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons.

Authors:  N Katsube; K Sunaga; D M Chuang; R Ishitani
Journal:  Neurosci Lett       Date:  1996-08-23       Impact factor: 3.046

6.  Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain.

Authors:  Gaëlle Bellemère; Philippe Morain; Hubert Vaudry; Sylvie Jégou
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

7.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats.

Authors:  K Toide; M Shinoda; T Fujiwara; Y Iwamoto
Journal:  Pharmacol Biochem Behav       Date:  1997-03       Impact factor: 3.533

8.  Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition.

Authors:  Ingo Schulz; Bernd Gerhartz; Antje Neubauer; Andreas Holloschi; Ulrich Heiser; Mathias Hafner; Hans-Ulrich Demuth
Journal:  Eur J Biochem       Date:  2002-12

Review 9.  Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex.

Authors:  Yasuo Kawaguchi; Satoru Kondo
Journal:  J Neurocytol       Date:  2002 Mar-Jun

10.  GAP43 stimulates inositol trisphosphate-mediated calcium release in response to hypotonicity.

Authors:  Marco Caprini; Ana Gomis; Hugo Cabedo; Rosa Planells-Cases; Carlos Belmonte; Félix Viana; Antonio Ferrer-Montiel
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

View more
  23 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

2.  MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition.

Authors:  Daniela Macconi; Susanna Tomasoni; Paola Romagnani; Piera Trionfini; Fabio Sangalli; Benedetta Mazzinghi; Paola Rizzo; Elena Lazzeri; Mauro Abbate; Giuseppe Remuzzi; Ariela Benigni
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

3.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

Review 5.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

6.  Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ.

Authors:  Da Zhou; Jing Wang; Ling-Nan He; Bing-Hang Li; Yong-Nian Ding; Yuan-Wen Chen; Jian-Gao Fan
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

7.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

8.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

9.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

10.  Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.

Authors:  Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V Levenson; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.